Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study)

Colaboración

Año: 2021

Abrisqueta, P; Loscertales, J; Terol, MJ; Payer, AR; Ortiz, M; Perez, I; Cuellar-Garcia, C; de la Mata, MF; Rodriguez, A; Lario, A; Delgado, J; Godoy, A; Perez, JMA; Berruezo, MJ; Oliveira, A; Hernandez-Rivas, JA; Malo, MDG; Medina, A; Martin, PG; Osorio,

Título: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

• Q3